EGFR and non-small cell lung carcinoma: Although erlotinib has been approved for second or third–line therapy for advanced NSCLC irrespective of EGFR mutation status, many studies have demonstrated that patients with KRAS mutations show inferior outcomes compared with those with wild-type KRAS [11–13].